Please assess the completion status of the following clinical trial:

Trial Title: Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 60 years or older~2. Diagnosis of Major Depressive Disorder, single or recurrent episode, without psychotic features by Diagnostic and Statistical Manual IV Text Revision (DSMIV-TR) criteria~3. Presence of hypertension (defined as systolic \> 140 or diastolic \> 90 or currently receiving antihypertensive therapy)~4. Minimum depression severity of ≥ 15 on the Montgomery-Asberg Depression Rating Scale (MADRS)~5. Cognitively intact or with mild cognitive deficits, with a minimum score ≥ 23 on the Montreal Cognitive Assessment (MoCA).~Exclusion Criteria:~1. Other psychiatric Axis I disorders~2. Acute suicidality~3. Electroconvulsive therapy in the last 6 months~4. Primary neurological disorder, including dementia and stroke~5. Significant cardiovascular disease, specifically diagnosis of congestive heart failure, known bilateral renal artery stenosis, symptomatic hypotension, or critical aortic or mitral stenosis~6. Myocardial infarction or open-heart surgery in last 6 weeks~7. Serum creatinine ≥ 265 micromol /L~8. Serum potassium ≥ 5.5 mmol/L~9. MRI contraindications~10. Known allergy to sertraline or candesartan specifically or known allergy to other SSRIs or ARBs.~11. History of prolonged (\> 3 weeks) or self-described severe discontinuation syndrome in the past after stopping an antidepressant.~12. Current use of an angiotensin receptor blocker~13. Current or planned psychotherapy~14. Need for continuous oxygen use or any medical disorder where the hypercapnia challenge would be contraindicated or put the subject at increased risk. This would include acute respiratory disease, chronic angina, or other unstable cardiac conditions.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1: Sertraline (Type: EXPERIMENTAL): Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
- Phase 2: Candesartan (Type: EXPERIMENTAL): For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).